Bridge Genomics brings together world leaders in genome and computational biology. We have pioneered new technologies to map and analyze large-scale genetic networks and are inventing new technologies to discover how combinations of different mutations encoded in our genomes impact susceptibility to disease and other inherited traits. Our mission is to improve diagnostics and therapeutics for disease through combinatorial analysis of human genetic data.
We’ve spent 15 years understanding the principles that govern genetic interactions using model organisms. Now we’re combining our deep expertise in functional genomics and computational biology to decode the mysteries of disease in human genetics.
MEET THE FOUNDERS
Who We Are
Chad is an Associate Professor in the Department of Computer Science and Engineering at the University of Minnesota. Chad’s research focuses on computational methods for analysis and interpretation of large-scale genetic interaction networks and methods for integration of diverse genomic data to predict gene function or infer biological networks. Working with Charlie Boone and Michael Costanzo, he measured interactions for millions of yeast mutants, leading to the first genetic network for any organism. Chad received his Ph.D. from the Department of Computer Science and the Lewis-Sigler Institute for Integrative Genomics at Princeton University.
Michael is a research scientist specializing in functional genomics. He led a research team to develop and implement high-throughput experimental and computational approaches for systems-level genetic analyses where the roles of all genes in an organism are examined simultaneously in a given assay. Michael received his PhD from the Department of Molecular Genetics at the University of Toronto.
Charlie is a Professor in the Department of Molecular Genetics at the University of Toronto and Donnelly Centre for Cellular and Biomolecular Research. His research is dedicated to high-throughput systems-level genetic analyses and he has pioneered technologies to map genetic interaction networks on a genome-wide scale which was instrumental to the development of BridGE Genomics’ core technology. Charlie founded Mycota Biosciences, a biotechnology start-up dedicated to antifungal drug discovery that was ultimately acquired by Merck. He has also worked closely with Singer Instruments (UK) and S&P Robotics to develop and market robotics for high-throughput biology.
Brenda is a Professor in the Department of Molecular Genetics at the University of Toronto and Director of the Donnelly Centre for Cellular and Biomolecular Research. Brenda is a Fellow of the Royal Society of Canada and a Companion to the Order of Canada. She serves on grant review panels and on several advisory boards. Brenda is an established leader in the fields of cell cycle biology and functional genomics and together with Charlie has invented several innovative technologies for high-throughput biology and automated genetic analysis.